ARIETIS

Basic Information

650 Albany St
Boston, MA, 02118-2518

Company Profile

n/a

Additional Details

Field Value
DUNS: 783349058
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Antibiotics for Recalcitrant Infection

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Narrow-spectrum Agents Acting against Helicobacter pylori

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Ro ...

    SBIR Phase II 2013 Department of Health and Human Services
  3. Compounds to treat Helicobacter pylori infection

    Amount: $585,967.00

    DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Narrow-spectrum Agents Acting against Helicobacter pylori

    Amount: $297,456.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Ro ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. 2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis

    Amount: $598,147.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to evaluate 2-adamantanamine compounds as a potential therapeutic to treat recurrent oropharyngeal candidiasis (OPC) in HIV pat ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Therapy Against Recalcitrant C. albicans Infection

    Amount: $2,984,771.00

    DESCRIPTION (provided by applicant): One of the important unresolved problems in fungal antimicrobial chemotherapy is the ineffectiveness of existing therapeutics against cells that do no exist in a r ...

    SBIR Phase II 2010 Department of Health and Human Services
  7. THERAPY AGAINST RECALCITRANT C. albicans INFECTION

    Amount: $599,243.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective therapy against relapsing vaginosis caused by Candida albicans. The disease occurs in 8-9% of all wom ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government